Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:United_States
gptkb:FDA gptkb:EMA |
| gptkbp:ATCCode |
L01XC41
|
| gptkbp:blackBoxWarning |
none
|
| gptkbp:combinationTherapy |
gptkb:rituximab
gptkb:bendamustine |
| gptkbp:drugClass |
gptkb:monoclonal_antibody
antineoplastic agent |
| gptkbp:genericName |
gptkb:polatuzumab_vedotin-piiq
|
| gptkbp:halfLife |
12 days
|
| https://www.w3.org/2000/01/rdf-schema#label |
Polivy
|
| gptkbp:indication |
diffuse large B-cell lymphoma
relapsed or refractory diffuse large B-cell lymphoma |
| gptkbp:manufacturer |
gptkb:Genentech
gptkb:Roche |
| gptkbp:mechanismOfAction |
gptkb:monoclonal_antibody
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
gptkb:anemia
fever diarrhea fatigue peripheral neuropathy neutropenia thrombocytopenia |
| gptkbp:target |
gptkb:CD79b
|
| gptkbp:bfsParent |
gptkb:Roche
|
| gptkbp:bfsLayer |
6
|